友華攜手日商搶攻癌症針劑新藥 2016年新廠完工年商機百億元 鉅亨網記者胡薏文 台北2012-11-0810:15 友華生技(4120-TW)搶攻癌症新藥商機邁大步，與日本前5大生技廠NanoCarrier，在台興建癌症針劑廠，預定投資7億元，新廠預定2013年動工，2016年可完工，初期預估全球年營收可達5億美元，商機可突破新台幣百億元。友華與NanoCarrier的合作建廠案，也為台日生技產業攜手開啟新頁，預定設立中部科學園區虎尾園區的新廠，將是 NanoCarrier全世界第一個生產廠，日方將全力參與這座新藥廠的規劃與建造，以通過美國FDA及日本厚生省查廠為目標，將所生產藥品的藥品供應全球市場。友華生技董事長蔡正弘表示，友華與NanoCarrier於2008年合作開發的抗癌新藥Nanoplatin，已進入第2期臨床試驗，由於研發進展順利，雙方決定進一步攜手合作，目前正在台灣、新加坡、香港、韓國及澳洲，針對胰臟癌病患展開查驗登記臨床試驗，預估2017年可獲准上市。至於頭頸癌，預計2014年第2季進入三期臨床試驗，預估2018年可獲准上市。由於友華與NanoCarrier合作開發抗癌新藥進展順利，因此雙方決定在台灣共同投資興建癌症針劑藥廠，生產Nanoplatin供應全球，跨入全球癌藥市場。友華前3季每股稅後盈餘為2.38元，在奶粉、代理藥品、美容保健等領域，營運與獲利都相當穩健，再添新藥商機，待新廠完工後，集團營運也將展翅高飛。
Cisplatin (generic name) is a platinum-based chemotherapy drug that is widely used to treat various types of cancers. By bonding with DNA in cancer cells, it interferes with the replication of DNA to stop division and multiplication of the cells and ultimately kills them. Although cisplatin is effective against tumors, it has number of side effects that limit its use. Major concern is nephrotoxicity (kidney damage). Patients need to be hospitalized to take hydration treatment in order to prevent renal damage. In addition, such digestive symptoms as nausea and vomiting, and poor appetite are observed. With the aim to develop new drugs that are expected to reduce the above mentioned side effects and to increase antitumor efficacy, NanoCarrier has prepared micellar nanoparticles containing cisplatin derivatives (NC-6004) , produced by a coordination bonds of cisplatin to polyamino acid. As NC-6004 showed sustained release, as well as accumulation in cancer cells and decrease in nephrotoxicity and neurotoxicity, in May 2006, we started the phase I clinical trial in U.K. The basic technology of this formulation was invented by Professor Kataoka of the University of Tokyo. The technology was licensed in from TOUDAI TLO Ltd. The basic Japanese patent has been granted as U.S. Pat. No. 7125546 and European Patent No. 1329221.
No comments:
Post a Comment